Related Experiment Video
Updated: Jun 25, 2025
12:46
Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
Published on: August 17, 2022
2.5K
Therapeutic Avenues to Modulate B-Cell Function in Patients With Cardiovascular Disease
James W O'Brien1, Ayden Case1, Claudia Kemper2
1Division of Cardiorespiratory Medicine, Department of Medicine, Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, United Kingdom (J.W.O., A.C., T.X.Z., Z.M.).
Arteriosclerosis, Thrombosis, and Vascular Biology
|May 30, 2024
Summary
B cells influence atherosclerosis, with innate-like responses being protective and adaptive responses having mixed effects. Therapeutic strategies targeting B cells, including depletion and modulation, are crucial for managing cardiovascular disease.
Area of Science:
- Immunology
- Cardiovascular Disease Research
- Therapeutic Target Identification
Background:
- The adaptive immune system significantly impacts atherosclerotic cardiovascular disease (ASCVD) development and progression.
- B cells exhibit dual roles in ASCVD, acting as both proatherogenic and atheroprotective factors.
- Modulating B-cell activity presents a key therapeutic avenue for cardiovascular disease.
Purpose of the Study:
- To review current therapeutic strategies targeting B cells in atherosclerotic cardiovascular disease.
- To elucidate the distinct roles of innate-like and adaptive B-cell responses in atherosclerosis.
- To explore the therapeutic potential of regulating B-cell interactions with other immune components.
Main Methods:
- Literature review of therapeutic approaches for B-cell modulation in ASCVD.
- Analysis of B-cell roles, encompassing antibody-dependent and independent functions.
- Examination of B-cell interactions with T cells and complement systems.
Main Results:
- Innate-like B-cell responses are generally atheroprotective.
- Adaptive B-cell responses have complex and mixed consequences for atherosclerosis.
- Interactions between B cells and other immune cells (T cells) and factors (complement) are critical for therapeutic regulation.
Conclusions:
- Targeting B-cell depletion and survival modulation offers therapeutic potential for ASCVD.
- Manipulating antibody-dependent and independent B-cell responses are viable treatment strategies.
- Emerging immunization techniques present novel approaches for managing B-cell mediated cardiovascular disease.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
432
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
432
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.4K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.4K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
709
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
709
01:24B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K